AR107298A1 - Método de purificación - Google Patents

Método de purificación

Info

Publication number
AR107298A1
AR107298A1 ARP170100022A ARP170100022A AR107298A1 AR 107298 A1 AR107298 A1 AR 107298A1 AR P170100022 A ARP170100022 A AR P170100022A AR P170100022 A ARP170100022 A AR P170100022A AR 107298 A1 AR107298 A1 AR 107298A1
Authority
AR
Argentina
Prior art keywords
complexed
solution
separation material
ions
mixture
Prior art date
Application number
ARP170100022A
Other languages
English (en)
Inventor
Olav B Ryan
Janne Olsen Frenvik
Original Assignee
Bayer As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer As filed Critical Bayer As
Publication of AR107298A1 publication Critical patent/AR107298A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/04—Processes using organic exchangers
    • B01J39/05—Processes using organic exchangers in the strongly acidic form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente proporciona un método para la purificación de ²²⁷Th complejado a partir de una mezcla que comprende ²²⁷Th complejado y ²²³Ra (complejado o en solución), comprendiendo dicho método: i) preparar una primera solución que comprende una mezcla de iones ²²⁷Th complejado e iones ²²³Ra en un primer buffer acuoso; ii) cargar dicha primera solución sobre un material de separación; iii) eluir ²²⁷Th complejado de dicho material de separación generando así una segunda solución que comprende ²²⁷Th complejado; iv) enjuagar opcionalmente dicho material de separación utilizando un primer medio de lavado acuoso. La presente proporciona adicionalmente una solución de ²²⁷Th purificado, un producto farmacéutico y su utilización en el tratamiento de enfermedades tales como el cáncer y un kit para la generación de dicho producto.
ARP170100022A 2016-01-05 2017-01-05 Método de purificación AR107298A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1600158.8A GB201600158D0 (en) 2016-01-05 2016-01-05 Purification method

Publications (1)

Publication Number Publication Date
AR107298A1 true AR107298A1 (es) 2018-04-18

Family

ID=55406719

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170100022A AR107298A1 (es) 2016-01-05 2017-01-05 Método de purificación

Country Status (10)

Country Link
US (2) US20190002363A1 (es)
EP (1) EP3400083A1 (es)
JP (1) JP2019509328A (es)
CN (1) CN108601991A (es)
AR (1) AR107298A1 (es)
CA (1) CA3010215A1 (es)
GB (1) GB201600158D0 (es)
TW (1) TW201726178A (es)
UY (1) UY37065A (es)
WO (1) WO2017118596A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114807636B (zh) * 2021-12-31 2023-10-20 中国工程物理研究院核物理与化学研究所 一种无载体177Lu和161Tb的GMP生产方法
WO2023159229A1 (en) 2022-02-21 2023-08-24 Bayer Healthcare Llc System, method and device for delivery of a therapeutic or diagnostic agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5035840A (en) * 1990-10-01 1991-07-30 Chemical Waste Management, Inc. Process for cleaning trace metals from EDTA
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
GB201105298D0 (en) * 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation
GB201208309D0 (en) * 2012-05-11 2012-06-27 Algeta As Complexes
GB201310028D0 (en) * 2013-06-05 2013-07-17 Algeta Asa Pharmaceutical preparation
US9951399B2 (en) * 2014-04-09 2018-04-24 Los Alamos National Security, Llc Separation of protactinum, actinium, and other radionuclides from proton irradiated thorium target

Also Published As

Publication number Publication date
GB201600158D0 (en) 2016-02-17
US20190002363A1 (en) 2019-01-03
TW201726178A (zh) 2017-08-01
CN108601991A (zh) 2018-09-28
US20210130253A1 (en) 2021-05-06
CA3010215A1 (en) 2017-07-13
JP2019509328A (ja) 2019-04-04
EP3400083A1 (en) 2018-11-14
UY37065A (es) 2017-07-31
WO2017118596A1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
BR112017012679A2 (pt) compostos imunomoduladores, seus usos, composição e kit
WO2016100261A3 (en) Method of treating cancer with cgamp or cgasmp
EP4374924A3 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EA201400178A1 (ru) Лечение рака молочной железы
BR112016020688A2 (pt) Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc)
BR112017016019A2 (pt) método para tratamento de câncer, artigo para fabricação, e, kit.
BR112013027500A2 (pt) liberação controlada de imunossupressores de nanotransportadores sintéticos
ECSP109934A (es) Compuesto - 946
UY33480A (es) Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento.
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
CL2017001592A1 (es) Complejos radiofarmacéuticos.
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
NI201800071A (es) Compuestos de isoindol
AR102463A1 (es) Inhibidor de cinasa aurora a
CL2016002318A1 (es) Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits.
PH12015500399A1 (en) Azaindolines
AR107298A1 (es) Método de purificación
UY37064A (es) Método de purificación
WO2019016597A3 (en) SYNTHETIC PROTEINS AND THEIR THERAPEUTIC USES
MX369414B (es) Peptido.
MX2018004696A (es) Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos.
AR085399A1 (es) Combinacion antitumoral que comprende cabazitaxel y cisplatino
AR107300A1 (es) Método para la preparación de isótopos

Legal Events

Date Code Title Description
FB Suspension of granting procedure